NKTR Nektar Therapeutics
Price (delayed)
$0.7558
Market cap
$140.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.58
Enterprise value
$198.97M
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.
Highlights
Nektar Therapeutics's EPS has surged by 60% YoY and by 31% QoQ
The net income has surged by 57% year-on-year and by 29% since the previous quarter
Nektar Therapeutics's equity has shrunk by 54% YoY but it has increased by 24% QoQ
Nektar Therapeutics's quick ratio has decreased by 30% YoY but it has increased by 15% from the previous quarter
Key stats
What are the main financial stats of NKTR
Market
Valuations
Earnings
Shares outstanding
186.1M
Market cap
$140.66M
Enterprise value
$198.97M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.3
Price to sales (P/S)
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.02
Revenue
$98.43M
Gross profit
$67.74M
Operating income
-$105.2M
Net income
-$118.96M
EBIT
-$91.09M
EBITDA
-$86.7M
Free cash flow
-$111.79M
Per share
Balance sheet
Liquidity
EPS
-$0.58
EPS diluted
-$0.58
Free cash flow per share
-$0.54
Book value per share
$0.33
Revenue per share
$0.48
TBVPS
$1.48
Total assets
$303.85M
Total liabilities
$243.11M
Debt
$102.56M
Equity
$60.74M
Working capital
$199.89M
Debt to equity
1.69
Current ratio
4.26
Quick ratio
4.16
Net debt/EBITDA
-0.67
Margins
Efficiency
Dividend
EBITDA margin
-88.1%
Gross margin
68.8%
Net margin
-120.9%
Operating margin
-106.9%
Return on assets
-35.2%
Return on equity
-150.6%
Return on invested capital
-26.1%
Return on capital employed
-37.6%
Return on sales
-92.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NKTR stock price
How has the Nektar Therapeutics stock price performed over time
Intraday
-2.49%
1 week
20.75%
1 month
2.37%
1 year
-42.74%
YTD
-18.73%
QTD
11.15%
Financial performance
How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$98.43M
Gross profit
$67.74M
Operating income
-$105.2M
Net income
-$118.96M
Gross margin
68.8%
Net margin
-120.9%
The operating margin has soared by 63% YoY and by 35% from the previous quarter
The net margin has soared by 61% YoY and by 33% QoQ
The operating income has soared by 60% year-on-year and by 31% since the previous quarter
The net income has surged by 57% year-on-year and by 29% since the previous quarter
Growth
What is Nektar Therapeutics's growth rate over time
Valuation
What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
2.3
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.02
Nektar Therapeutics's EPS has surged by 60% YoY and by 31% QoQ
Nektar Therapeutics's equity has shrunk by 54% YoY but it has increased by 24% QoQ
The P/B is 23% below the last 4 quarters average of 3.0
The stock's P/S is 86% less than its 5-year quarterly average of 11.7 and 34% less than its last 4 quarters average of 2.4
The revenue has grown by 9% YoY and by 6% from the previous quarter
Efficiency
How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has surged by 67% YoY and by 40% QoQ
The return on invested capital has grown by 49% year-on-year and by 31% since the previous quarter
NKTR's ROA is up by 40% YoY and by 24% from the previous quarter
Nektar Therapeutics's ROE has increased by 14% from the previous quarter
Dividends
What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NKTR.
Financial health
How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 25% more than its total liabilities
The company's current ratio fell by 34% YoY
Nektar Therapeutics's quick ratio has decreased by 30% YoY but it has increased by 15% from the previous quarter
The debt is 69% higher than the equity
The debt to equity has soared by 88% YoY but it fell by 24% QoQ
Nektar Therapeutics's equity has shrunk by 54% YoY but it has increased by 24% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.